For example, Bosutinib, a dual kinase inhibitor of both the BCR-ABL and Src tyrosine kinases and is used in the therapy of Philadelphia chromosome-positive chronic myelogenous leukemia, has lower IC50 in the low-risk group. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.